EV00 Stock Overview
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Evoke Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.37 |
| 52 Week High | US$2.14 |
| 52 Week Low | US$0.37 |
| Beta | 0.30 |
| 1 Month Change | -29.43% |
| 3 Month Change | -36.07% |
| 1 Year Change | -78.13% |
| 3 Year Change | -97.79% |
| 5 Year Change | -95.05% |
| Change since IPO | -99.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| EV00 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -25.2% | 2.3% | 0.5% |
| 1Y | -78.1% | -28.6% | 1.3% |
Price Volatility
| EV00 volatility | |
|---|---|
| EV00 Average Weekly Movement | 13.4% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: EV00's share price has been volatile over the past 3 months.
Volatility Over Time: EV00's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 4 | Matt D'Onofrio | www.evokepharma.com |
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers.
Evoke Pharma, Inc. Fundamentals Summary
| EV00 fundamental statistics | |
|---|---|
| Market cap | €3.54m |
| Earnings (TTM) | -€7.26m |
| Revenue (TTM) | €4.83m |
0.7x
P/S Ratio-0.5x
P/E RatioIs EV00 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EV00 income statement (TTM) | |
|---|---|
| Revenue | US$5.18m |
| Cost of Revenue | US$201.88k |
| Gross Profit | US$4.98m |
| Other Expenses | US$12.77m |
| Earnings | -US$7.79m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.92 |
| Gross Margin | 96.10% |
| Net Profit Margin | -150.41% |
| Debt/Equity Ratio | -193.8% |
How did EV00 perform over the long term?
See historical performance and comparison